Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients

Area of Science:

• Cardiology
• Pharmacology
• Physiology

Background:

• Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are recommended for heart failure (HF) treatment.
• Large trials confirm SGLT-2i benefits for cardiovascular outcomes in HF patients.
• Mechanisms underlying SGLT-2i efficacy in HF require further elucidation.

Purpose of the Study:

• To assess the hemodynamic effects of SGLT-2 inhibitors in heart failure patients.
• To review current literature on SGLT-2i's impact on cardiac function.
• To stratify findings based on left ventricular ejection fraction (LVEF).

Main Methods:

• Literature review of studies on SGLT-2 inhibitors in heart failure.
• Analysis of hemodynamic parameters: LV preload, filling pressures, pulmonary artery pressure, cardiac output, and afterload.
• Stratification of data for HF with reduced LVEF (HFrEF) and HF with preserved LVEF (HFpEF).

Main Results:

• SGLT-2 inhibition influences key hemodynamic variables in HF.
• Effects on preload, cardiac output, and afterload are detailed for HFrEF and HFpEF.
• Evidence linking SGLT-2i-induced hemodynamic changes to LV remodeling is examined.

Conclusions:

• SGLT-2 inhibitors exert significant hemodynamic effects in heart failure.
• Understanding these mechanisms is crucial for optimizing HF management.
• Further research into SGLT-2i's impact on cardiac structure and function is warranted.